S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Illumina Stock Forecast, Price & News

+6.68 (+3.62%)
(As of 07/1/2022 05:43 PM ET)
Today's Range
50-Day Range
52-Week Range
1.12 million shs
Average Volume
1.79 million shs
Market Capitalization
$30.01 billion
P/E Ratio
Dividend Yield
Price Target

Illumina MarketRank™ Forecast

Analyst Rating
2.33 Rating Score
122.5% Upside
$425.09 Price Target
Short Interest
2.18% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.39mentions of Illumina in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth
From $4.10 to $5.28 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.44 out of 5 stars

Medical Sector

118th out of 1,412 stocks

Analytical Instruments Industry

5th out of 33 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Illumina logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

ILMN Stock News Headlines

Illumina (NASDAQ:ILMN) Reaches New 12-Month Low at $184.04
Illumina (NASDAQ:ILMN) Reaches New 12-Month Low at $196.89
Why Illumina Stock Is Sinking Today
See More Headlines

Industry, Sector and Symbol

Analytical instruments
Life Sciences Tools & Services
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$762 million
Pretax Margin


Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.52 per share
Book Value
$68.71 per share


Free Float
Market Cap
$30.01 billion

Social Links

Illumina Frequently Asked Questions

Should I buy or sell Illumina stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

What is Illumina's stock price forecast for 2022?

9 brokerages have issued 1-year price objectives for Illumina's shares. Their ILMN stock forecasts range from $325.00 to $520.00. On average, they anticipate Illumina's stock price to reach $425.09 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

How has Illumina's stock price performed in 2022?

Illumina's stock was trading at $380.44 at the beginning of the year. Since then, ILMN stock has decreased by 49.8% and is now trading at $191.04.
View the best growth stocks for 2022 here

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Illumina

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings data on Thursday, May, 5th. The life sciences company reported $1.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $0.20. The life sciences company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.22 billion. Illumina had a trailing twelve-month return on equity of 8.37% and a net margin of 15.04%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.89 earnings per share.
View Illumina's earnings history

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of $4.00-$4.20 for the period, compared to the consensus estimate of $4.15. The company issued revenue guidance of $5.16 billion-$5.25 billion, compared to the consensus revenue estimate of $5.23 billion.

Who are Illumina's key executives?

Illumina's management team includes the following people:

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $191.04.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $30.01 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or $4.599990 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Enancio SAS, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More

When was Illumina founded?

Illumina was founded in 1998.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for Illumina is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.